Dengue virus infection: a major cause of acute hepatic failure in Thai children

Authors: Poovorawan, Yong1; Hutagalung, Yanee2; Chongsrisawat, Voranush1; Boudville, Irving2; Bock, Hans L.2

Source: Annals of Tropical Paediatrics: International Child Health, Volume 26, Number 1, March 2006 , pp. 17-23(7)

Publisher: Maney Publishing

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content

Abstract:

Background: Acute hepatic failure (AHF) can be caused by a variety of viruses, drugs, toxins and metabolic disorders.

Aims: A prospective study was conducted to determine the aetiology and outcome of AHF in Thai children aged 1–15 years.

Methods: All serum samples were tested for anti-HAV IgM, HBsAg, anti-HBc IgM, anti-HCV, anti-HEV IgM and anti-dengue IgG and IgM. Further individual investigations were done according to the clinical impression.

Results: Forty subjects were enrolled from 14 centres during February 2000 to December 2001. Five cases were excluded owing to a lack of evidence of encephalopathy. The causes of AHF were dengue infection in 12 (34.3%), Wilson disease in 2 (5.7%), T-cell lymphoma in 2 (5.7%), ischaemic hepatitis in two (5.7%), haemophagocytic syndrome in one (2.8%), CMV in 2 (5.7%), Reye syndrome in one (2.8%) and unknown in 13 (37.1%) patients. The fatality rate was 68.6%. Eight of 24 (33.3%) deaths were caused by dengue infection.

Conclusions: Improvements in sanitation and socio-economic status as well as the implementation of hepatitis B vaccine in the Extended Programme on Immunization (EPI) are likely to be the reasons for the observed absence of AHF caused by hepatitis A and B. The study showed that dengue infection, on the other hand, was a major cause of AHF in Thailand.

Document Type: Research article

DOI: 10.1179/146532806X90565

Affiliations: 1: Center of Excellence in Viral Hepatitis Research, Department of Pediatrics, Faculty of Medicine,Chulalongkorn University and Hospital, Bangkok, Thailand 2: GlaxoSmithKline Biologicals, Rixensart, Belgium

Your trusted access to this article has expired.

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.00 plus tax      Refund Policy

 

OR

Back to top

Key:
Free Content - Free Content
New Content - New Content
Subscribed Content - Subscribed Content
Free Trial Content - Free Trial Content
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in






Need to register?
Sign up here
Text size: A | A | A | A